AVEO Pharmaceuticals, Inc.
AVEO
AVEO was delisted on the 19th of January, 2023.
35 hedge funds and large institutions have $15.6M invested in AVEO Pharmaceuticals, Inc. in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 30 closing their positions.
15% more call options, than puts
Call options by funds: $4.06M | Put options by funds: $3.54M
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
41% less capital invested
Capital invested by funds: $26.5M → $15.6M (-$11M)
43% less funds holding
Funds holding: 61 → 35 (-26)
77% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$557K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$194K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$48K |
| 4 |
WA
WealthTrust Axiom
Wayne,
Pennsylvania
|
+$39.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$212K |
| 2 |
Bank of New York Mellon
New York
|
-$61K |
| 3 |
State Street
Boston,
Massachusetts
|
-$50K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$48K |
| 5 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
-$42K |
AVEO Hedge Fund Activity: Q1 2020 in Review
35 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q1 2020, worth a combined $15.6M — down 41% from $26.5M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of AVEO and 7 opened new positions — a net loss of 23 holders — while 12 trimmed existing stakes and 12 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $557K. The largest seller was Millennium Management, exiting entirely with an estimated $212K sold.
- 35 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q1 2020, down from 61 in Q4 2019.
- Funds reported $15.6M of AVEO Pharmaceuticals, Inc. stock for Q1 2020, down 41% quarter-over-quarter.
- 7 funds opened new AVEO Pharmaceuticals, Inc. positions in Q1 2020 and 30 closed out, a net change of -23 holders.
- The largest AVEO Pharmaceuticals, Inc. buyer in Q1 2020 was Sabby Management, an estimated $557K added.
- The largest AVEO Pharmaceuticals, Inc. seller in Q1 2020 was Millennium Management, an estimated $212K sold.
Based on aggregated 13F filings for Q1 2020.